Stocks and Investing
Stocks and Investing
Wed, August 9, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Anthony Butler Reiterated (ATRA) at Strong Buy and Held Target at $625 on, Aug 9th, 2023
Anthony Butler of EF Hutton, Reiterated "Atara Biotherapeutics, Inc." (ATRA) at Strong Buy and Held Target at $625 on, Aug 9th, 2023.
Anthony has made no other calls on ATRA in the last 4 months.
There are 2 other peers that have a rating on ATRA. Out of the 2 peers that are also analyzing ATRA, 0 agree with Anthony's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Anthony
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $700 on, Wednesday, June 14th, 2023
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $500 on, Tuesday, May 9th, 2023
Contributing Sources